• BioInvent’s board finalized terms on November 5, 2026, for a rights issue expected to raise approximately SEK 428 million before costs.
• The issue comprises up to 427,728,353 new shares at SEK 1 each, with 2 subscription rights entitling holders to 13 new shares.
• Additional guarantees of approximately SEK 78 million bring coverage to 100%; the cash guarantee fee rises from 11% to 12%.
• The rights issue requires shareholder approval at the December 1, 2026, extraordinary general meeting.
• Proceeds will fund priority clinical programs, principally solid-tumor development of BI-1808 and BI-1206.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.